I’ve been reflecting on why gene therapies can show strong clinical benefit yet still face uneven access across Europe, especially in ultra-rare diseases like MLD. What do you think should be the main priority for improving access in a sustainable way? Share your insights by voting below!

What should be the top priority for improving gene therapy access across Europe?